Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688319'
s PB Ratio Range Over the Past 10 Years
Min: 3.43 Med: 8.77 Max: 36.29
Current: 11.83
During the past 13 years, Chengdu Olymvax Biopharmaceuticals's highest PB Ratio was 36.29. The lowest was 3.43. And the median was 8.77.
SHSE:688319's PB Ratio is ranked worse than 88.37% of 1230
companies
in the Biotechnology industry
Industry Median: 2.82
vs SHSE:688319: 11.83
During the past 12 months, Chengdu Olymvax Biopharmaceuticals's average Book Value Per Share Growth Rate was 1.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 0.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 12.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Chengdu Olymvax Biopharmaceuticals was 32.50% per year. The lowest was -2.00% per year. And the median was 2.70% per year.
Back to Basics: PB Ratio
Chengdu Olymvax Biopharmaceuticals (SHSE:688319) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Chengdu Olymvax Biopharmaceuticals PB Ratio Related Terms
Chengdu Olymvax Biopharmaceuticals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688319 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Chengdu Olymvax Biopharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Olymvax Biopharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Olymvax Biopharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Chengdu Olymvax Biopharmaceuticals's PB Ratio falls into.
Chengdu Olymvax Biopharmaceuticals PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Chengdu Olymvax Biopharmaceuticals (SHSE:688319) has a PB Ratio of 11.80 as of Jul. 23, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors. This is 35% above median its historical median of 8.77. Over the past decade, Chengdu Olymvax Biopharmaceuticals' PB Ratio has ranged from 3.43 to 36.29. According to the industry distribution chart, Chengdu Olymvax Biopharmaceuticals ranks #1087 out of 1230 companies in the Biotechnology industry, placing it in the top 88.4%.
Is Chengdu Olymvax Biopharmaceuticals' PB Ratio too high?
Chengdu Olymvax Biopharmaceuticals' current PB Ratio of 11.80 is 35% above median its 10-year median of 8.77. Over the past 10 years, this metric has ranged from a low of 3.43 to a high of 36.29. The Biotechnology industry median PB Ratio is 2.82. Chengdu Olymvax Biopharmaceuticals' value of 11.80 is 318.4% above this industry median. Based on the distribution chart, Chengdu Olymvax Biopharmaceuticals ranks #1087 out of 1230 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chengdu Olymvax Biopharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Olymvax Biopharmaceuticals' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Olymvax Biopharmaceuticals ranks #1087 out of 1230 companies for PB Ratio. This places Chengdu Olymvax Biopharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.82. Chengdu Olymvax Biopharmaceuticals' value of 11.80 is 318.4% above this benchmark. Historically, Chengdu Olymvax Biopharmaceuticals' own PB Ratio has ranged from 3.43 to 36.29 over the past decade. While the company's 10-year median is 8.77 vs. the industry median of 2.82, Chengdu Olymvax Biopharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengdu Olymvax Biopharmaceuticals's current PB Ratio of 11.80 is 318.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengdu Olymvax Biopharmaceuticals's current PB Ratio is 11.80, which is 35% above median its own 10-year median of 8.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Olymvax Biopharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals (SHSE:688319) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥23.13, compared to a current price of ¥27.08 — trading 17.1% above its estimated fair value. The current PB Ratio is 11.80, which is 35% above median its 10-year median of 8.77 and 318.4% above the Biotechnology industry median of 2.82. Chengdu Olymvax Biopharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Chengdu Olymvax Biopharmaceuticals (SHSE:688319), the current PB Ratio is 11.80 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals stock appears to be overvalued.
The current stock price of ¥27.08 is trading 17.1% above its estimated GF Value™ of ¥23.13.
GuruFocus considers Chengdu Olymvax Biopharmaceuticals to be Modestly Overvalued.
Key valuation signals for SHSE:688319:
PB Ratio: 11.80 (35% above median its 10-year median of 8.77)
GF Value™: ¥23.13 vs. price of ¥27.08 (17.1% above fair value)
Industry Position: 318.4% above the Biotechnology median (#1087 of 1230)
No single metric tells the full story. See the SHSE:688319 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Olymvax Biopharmaceuticals Business Description
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
73GF Score
Get the complete analysis for SHSE:688319
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688319 has been successfully added to your 
